Please provide your email address to receive an email when new articles are posted on . The prevalence of food allergy in adults and children is growing. Omalizumab is not a cure, and patients must ...

Xolair, an antibody asthma drug, was recently approved for severe food allergic reactions. It is not the first biological drug to treat multiple conditions. But it is the first to treat severe food ...

Omalizumab, currently used to treat asthma, has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food allergies, ...

Please provide your email address to receive an email when new articles are posted on . Robert A. Wood, MD, FAAAAI, looks back on the first year of omalizumab’s use for food allergy. Patients often ...

Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...

WASHINGTON -- Regular courses of omalizumab (Xolair) injections increased the amount of peanut and other foods that multi-food allergic children could consume without an allergic reaction, data from ...

CHICAGO (WLS) -- After the FDA approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods, sufferers say they're ...

(Reuters) - Xolair, a 20-year-old asthma drug sold by Roche and Novartis, significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers ...

In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results. Adobe stock/HealthDay More than a ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair ...

The US Food and Drug Administration (FDA) has approved omalizumab injection (Xolair, Genentech) for children aged 1 year or older and adults to reduce immunoglobulin E─mediated severe allergy to ...